At the same time, the higher gene expression levels of Kir2.1, Kir3.1, and a lower gene expression level of Cav1.2 were also represented in the OSA group, although these levels were not attenuated after LLVS was administered. The gene discussed is KCNJ3; the disease is obstructive sleep apnea syndrome.